Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-10-13 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about partnerships to expand manufacturing for a COVID-19 therapeutic candidate. Form 6-K is a periodic report for foreign private issuers to disclose material information. The document is short (2158 characters) and primarily serves as a regulatory filing to report current events or press releases, not a full financial report or earnings release. It does not contain detailed financial statements or comprehensive management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-10-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about adding Israel rights to a product from AstraZeneca. The document length is 2114 characters, which is relatively short and primarily serves as a regulatory filing to report material information between annual reports. There is no detailed financial data, management discussion, or comprehensive report content. The document is not an annual report, earnings release, or detailed investor presentation. It is a regulatory announcement filed with the SEC to comply with disclosure requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-10-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is used for submitting reports of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The content includes a press release about a COVID-19 study passing a committee review, and it references incorporation by reference into registration statements. The document length is 2135 characters, which is relatively short and primarily serves as a report submission rather than a full financial or management report. Form 6-K filings are generally considered Regulatory Filings (RNS) as they are periodic reports that do not fit into other specific categories like Annual Reports or Earnings Releases. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-10-07 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about the company's presentation at investor conferences. The document length is short (2133 characters) and it primarily serves as a regulatory update filing rather than a full financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed earnings data. It also does not announce voting results, capital changes, or legal proceedings. Given these characteristics and the nature of Form 6-K filings, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about the approval of a Phase 2/3 COVID-19 study. The document is short (2128 characters) and primarily serves as a regulatory announcement attaching a press release. It does not contain detailed financial data, management discussion, or full report content. According to the rules, such filings are classified as Regulatory Filings (RNS) because they are miscellaneous regulatory announcements that do not fit other specific categories and are not full reports themselves.
2020-09-22 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a Notice of Extraordinary General Meeting of Shareholders and a Proxy Statement for that meeting. The content focuses on soliciting shareholder votes on various proposals, including amendments to compensation policies, articles of association, employment terms of executives, and option repricing. There are no financial statements or detailed financial performance data present. The document is not an annual or interim report, earnings release, or audit report. It is not a simple announcement of a report but rather the actual proxy materials and meeting notice. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI). Therefore, the correct classification is PSI with high confidence.
2020-09-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.